Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL CANCER TUBULIN INHIBITORS INDUSTRY
2.1 Summary about Cancer Tubulin Inhibitors Industry
2.2 Cancer Tubulin Inhibitors Market Trends
2.2.1 Cancer Tubulin Inhibitors Production & Consumption Trends
2.2.2 Cancer Tubulin Inhibitors Demand Structure Trends
2.3 Cancer Tubulin Inhibitors Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Docetaxel
4.2.2 Trastuzumab Emtansine
4.2.3 Abraxane
4.2.4 Brentuximab Vedotin
4.2.5 Cabazitaxel
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Non Small Cell Lung Cancer
4.3.2 Prostate Cancer
4.3.3 Breast Cancer
4.3.4 Colorectal Cancer
4.3.5 Ovarian Cancer
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Docetaxel
5.2.2 Trastuzumab Emtansine
5.2.3 Abraxane
5.2.4 Brentuximab Vedotin
5.2.5 Cabazitaxel
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Non Small Cell Lung Cancer
5.3.2 Prostate Cancer
5.3.3 Breast Cancer
5.3.4 Colorectal Cancer
5.3.5 Ovarian Cancer
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Docetaxel
6.2.2 Trastuzumab Emtansine
6.2.3 Abraxane
6.2.4 Brentuximab Vedotin
6.2.5 Cabazitaxel
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Non Small Cell Lung Cancer
6.3.2 Prostate Cancer
6.3.3 Breast Cancer
6.3.4 Colorectal Cancer
6.3.5 Ovarian Cancer
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Docetaxel
7.2.2 Trastuzumab Emtansine
7.2.3 Abraxane
7.2.4 Brentuximab Vedotin
7.2.5 Cabazitaxel
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Non Small Cell Lung Cancer
7.3.2 Prostate Cancer
7.3.3 Breast Cancer
7.3.4 Colorectal Cancer
7.3.5 Ovarian Cancer
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Docetaxel
8.2.2 Trastuzumab Emtansine
8.2.3 Abraxane
8.2.4 Brentuximab Vedotin
8.2.5 Cabazitaxel
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Non Small Cell Lung Cancer
8.3.2 Prostate Cancer
8.3.3 Breast Cancer
8.3.4 Colorectal Cancer
8.3.5 Ovarian Cancer
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Docetaxel
9.2.2 Trastuzumab Emtansine
9.2.3 Abraxane
9.2.4 Brentuximab Vedotin
9.2.5 Cabazitaxel
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Non Small Cell Lung Cancer
9.3.2 Prostate Cancer
9.3.3 Breast Cancer
9.3.4 Colorectal Cancer
9.3.5 Ovarian Cancer
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Abraxis Biosciences
10.1.2 Agensys
10.1.3 Amgen
10.1.4 Celgene
10.1.5 Eagle Pharmaceuticals
10.1.6 Endocyte
10.1.7 Genentech
10.1.8 Immunogen
10.1.9 Modra Pharmaceuticals
10.1.10 Pierre Fabre
10.1.11 Roche
10.1.12 Sanofi-Aventis
10.1.13 Seattle Genetics
10.1.14 Tocris Bioscience
10.2 Cancer Tubulin Inhibitors Sales Date of Major Players (2017-2020e)
10.2.1 Abraxis Biosciences
10.2.2 Agensys
10.2.3 Amgen
10.2.4 Celgene
10.2.5 Eagle Pharmaceuticals
10.2.6 Endocyte
10.2.7 Genentech
10.2.8 Immunogen
10.2.9 Modra Pharmaceuticals
10.2.10 Pierre Fabre
10.2.11 Roche
10.2.12 Sanofi-Aventis
10.2.13 Seattle Genetics
10.2.14 Tocris Bioscience
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
